|
|
Workshop on Cancer Biometrics: Identifying Biomarkers
and Surrogates of Cancer in Patients: A Meeting Held at the Masur Auditorium, National
Institutes of Health.
Lotze MT, Wang E, Marincola FM, Hanna N, Bugelski PJ,
Burns CA, Coukos G, Damle N, Godfrey TE, Howell WM, Panelli MC, Perricone MA, Petricoin EF,
Sauter G, Scheibenbogen C, Shivers SC, Taylor DL, Weinstein JN, Whiteside TL.
J Immunother. 2005 March/April;28(2):79-119.
 |
Abstract:
The current excitement about molecular targeted therapies has driven much of the recent
dialog in cancer diagnosis and treatment. Particularly in the biologic therapy of cancer,
identifiable antigenic T-cell targets restricted by MHC molecules and the related novel
stress molecules such as MICA/B and Letal allow a degree of precision previously unknown
in cancer therapy. We have previously held workshops on immunologic monitoring and angiogenesis
monitoring. This workshop was designed to discuss the state of the art in identification of
biomarkers and surrogates of tumor in patients with cancer, with particular emphasis on
assays within the blood and tumor. We distinguish this from immunologic monitoring in the
sense that it is primarily a measure of the tumor burden as opposed to the immune response to it.
Recommendations for intensive investigation and targeted funding to enable such strategies were
developed in seven areas: genomic analysis; detection of molecular markers in peripheral blood
and lymph node by tumor capture and RT-PCR; serum, plasma, and tumor proteomics; immune
polymorphisms; high content screening using flow and imaging cytometry; immunohistochemistry
and tissue microarrays; and assessment of immune infiltrate and necrosis in tumors. Concrete
recommendations for current application and enabling further development in cancer biometrics
are summarized. This will allow a more informed, rapid, and accurate assessment of novel
cancer therapies.
|
